The abstract is read at the publisher; the summary is JClub's.
PD-L1-overexpressing mesenchymal stromal/stem cells and their extracellular vesicles suppress T-cell activity, enhance regulatory T cells, delay type 1 diabetes onset, and reduce immune infiltration in pancreatic islets.
- Why it matters: Type 1 diabetes urgently needs new therapies that can modulate immune responses and protect pancreatic islets while promoting immune tolerance.
- What they did: The study tested PD-L1-MSCs and their extracellular vesicles for effects on immune modulation and pancreatic islet protection, including whether outcomes depend on PD-L1 signaling.
- The result: Both PD-L1-MSCs and PEVs suppress T-cell activity, increase regulatory T-cell populations, delay diabetes onset, and reduce immune cell infiltration, supporting their potential as immune-tolerant, β-cell–preserving strategies.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.